Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Croconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 1/20 | 0.98 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.98 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.98 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.98 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.98 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.98 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.98 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.98 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.98 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.98 |
| ▸ | ADRB2 known ✓ | P07550 | 10/20 | 0.52 |
| ▸ | ADRB1 known ✓ | P08588 | 10/20 | 0.52 |
| ▸ | ADRB3 known ✓ | P13945 | 10/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | CNR1 | P21554 | 1/20 | 0.98 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.98 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Croconazole SCHEMBL34369 | 0.99 | NR1I2 (1.00) | NR1I2NR3C1HTR1AADORA3CNR1 | |
| Croconazole SCHEMBL7601955 | 0.99 | NR1I2 (1.00) | NR1I2NR3C1HTR1AADORA3CNR1 | |
| Croconazole SCHEMBL29378466 | 0.99 | NR1I2 (1.00) | NR1I2NR3C1HTR1AADORA3CNR1 | |
| Croconazole SCHEMBL121863 | 0.98 | NR1I2 (0.98) | NR1I2NR3C1HTR1AADORA3CNR1 | |
| Croconazole SCHEMBL3690346 | 0.93 | NR1I2 (0.85) | NR1I2NR3C1HTR1AADORA3CNR1 | |
| Croconazole SCHEMBL1274172 | 0.92 | NR1I2 (0.86) | NR1I2NR3C1HTR1AADORA3CNR1 | |
| SCHEMBL11090539 | 0.86 | NR1I2 (0.78) | NR1I2NR3C1HTR1AADORA3CNR1 | |
| SCHEMBL2449293 | 0.83 | HTR1A (0.73) | NR1I2NR3C1HTR1AADORA3CNR1 | |
| SCHEMBL2449294 | 0.83 | HTR1A (0.73) | NR1I2NR3C1HTR1AADORA3CNR1 | |
| SCHEMBL30680200 | 0.83 | HTR1A (0.72) | NR1I2NR3C1HTR1AADORA3CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| US-20240173512-A1 | METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS | STREETERVILLE CAPITAL, LLC | 2024-05-30 | — | — | US | claimed |
| US-11890421-B2 | Methods for potentiating antimicrobial agents | BEYOND AIR LTD (IL) | 2024-02-06 | — | — | US | claimed |
| CN-115474430-A | Composition for treatment and/or prevention of coronavirus infection | 弗劳恩霍夫应用研究促进协会 | 2022-12-13 | — | — | CN | claimed |
| US-20200246573-A1 | NITRIC OXIDE INHALATION THERAPY FOR INFANTS WITH BRONCHIOLITIS | STREETERVILLE CAPITAL, LLC | 2020-08-06 | — | — | US | claimed |
| EP-2953624-B1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | LUODA PHARMA LTD (IE) | 2019-08-21 | — | — | EP | claimed |
| US-20160158261-A1 | Antibiotic Kit and Composition and Uses Thereof | FOAMIX LTD. (IL) | 2016-06-09 | — | — | US | claimed |
| US-20160000748-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | Luoda Pharma Limited (IE) | 2016-01-07 | — | — | US | claimed |
| US-20150366797-A1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | Luoda Pharma Limited (IE) | 2015-12-24 | — | — | US | claimed |
| EP-2953624-A1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | Luoda Pharma Pty Ltd (AU) | 2015-12-16 | — | — | EP | claimed |
| WO-2013112548-A1 | GAMMA-AAPEPTIDES WITH POTENT AND BROAD-SPECTRUM ANTIMICROBIAL ACTIVITY | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-08-01 | — | — | WO | claimed |
| EP-1919449-A2 | ANTIBIOTIC KIT AND COMPOSITION AND USES THEREOF | Foamix Ltd. (IL) | 2008-05-14 | — | — | EP | claimed |
| WO-2007099396-A2 | ANTIBIOTIC KIT AND COMPOSITION AND USES THEREOF | FOAMIX LTD. (US) | 2007-09-07 | — | — | WO | claimed |
| US-20060269485-A1 | Antibiotic kit and composition and uses thereof | FOAMIX LTD. (IL) | 2006-11-30 | — | — | US | claimed |
| EP-1696855-A1 | DERMAL DRUG DELIVERY SYSTEM | Medpharm Limited (GB) | 2006-09-06 | — | — | EP | claimed |
| US-20060130266-A1 | Dermal drug delivery system | MEDPHARM LIMITED (GB) | 2006-06-22 | — | — | US | claimed |
| WO-2005058226-A1 | DERMAL DRUG DELIVERY SYSTEM | MEDPHARM LIMITED (GB) | 2005-06-30 | — | — | WO | claimed |
| EP-0319965-B1 | PHARMACEUTICAL PREPARATION FOR TINEA PEDIS | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1991-03-13 | — | — | EP | claimed |
| US-4935241-A | CROCONAZOLE HYDROCHLORIDE AND ETHYL ACRYLATE-METHYL METHACRYLATE COPOLYMER | SHIONOGI & CO., LTD. (JP) | 1990-06-19 | — | — | US | claimed |
| EP-0319965-A1 | Pharmaceutical preparation for tinea pedis | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1989-06-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000748-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | TSLP, CCL11, IL17A | NR3C1 1967/4885HTR1A 4698/4885SLC6A2 1786/4885 |
| US-20150366797-A1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | LCT, TSLP, MLEC | NR3C1 886/4885HTR1A 4847/4885SLC6A2 2157/4885 |
| US-20160158261-A1 | Antibiotic Kit and Composition and Uses Thereof | KIT, RAB5IF, CUTA | NR3C1 3320/4885HTR1A 4257/4885SLC6A2 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.